Related references
Note: Only part of the references are listed.In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States
Chris M. Pillar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures
Aryun Kim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections
John F. Mohr
CLINICAL INFECTIOUS DISEASES (2008)
Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens
Garyphallia Poulakou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis
Kim L. Credito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Setting and revising antibacterial susceptibility breakpoints
John Turnidge et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004
C. Andrew DeRyke et al.
PHARMACOTHERAPY (2007)
Two decades of imipenem therapy
A. C. Rodloff et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections
Joseph L. Kuti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)
TR Fritsche et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates
HM Wexler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Use of pharmacokinetic-pharmaco dynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
SM Bhavnani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms
RN Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases
S Mushtaq et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Doripenem versus Pseudomonas aeruginosa in vitro:: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential
S Mushtaq et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Activities of doripenem (S-4661) against drug-resistant clinical pathogens
RN Jones et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Doripenem (S-4661), a novel carbapenem:: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
RN Jones et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Safety and tolerability of ertapenem
H Teppler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion
PK Dandekar et al.
PHARMACOTHERAPY (2003)
Comparative pharmacokinetics of the carbapenems - Clinical implications
JW Mouton et al.
CLINICAL PHARMACOKINETICS (2000)
Share Paper
